EXUMA
LIVE

Serial Number

97544808

Owner

Exuma Biotech Corp.

Attorney

Alison M. Caless

Filing Date

Aug 11, 2022

Add to watchlist:

No watchlists yet
View on USPTO

EXUMA Trademark

Serial Number: 97544808

EXUMA is a trademark filed by Exuma Biotech Corp. on August 11, 2022. The trademark is classified under Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Exuma Biotech Corp.

Suite 625
West Palm Beach, FL 33401

Entity Type: 03

Trademark Details

Filing Date

August 11, 2022

Registration Date

Not Registered

Published for Opposition

March 12, 2024

Goods & Services

Custom manufacturing of medical products in the nature of biological tissue, blood, viruses, and cells; custom manufacturing of pharmaceutical preparations for immunotherapy, including gene therapy, CAR T cell therapy, and cell therapy; custom manufacturing of biological preparations for the treatment of cancer

Bacteriological research; biological research; medical and scientific research, namely, conducting clinical trials for others; medical research; virological research; medical laboratory services; scientific research; development of pharmaceutical preparations and drugs; development of pharmaceutical preparations and drugs, namely, processing blood to isolate leukocytes for the creation of immunotherapies; scientific and medical research and development of pharmaceutical preparations and drugs; computer programming in relation to medicine and medical research; research in the field of stem cells

Medicines for human purposes in the nature of pharmaceutical preparations for gene and cell therapy, immunotherapy and the treatment of cancer, immunological diseases and disorders, genetic disorders, rare diseases, and infectious diseases; biological preparations for medical treatment of cancer, immunological diseases and disorders, genetic disorders, rare diseases, gene and cell therapy, and infectious diseases for humans and animals; medical biological tissue cultures and viruses for the prevention and treatment of cancer for humans and animals; drug products in the nature of pharmaceutical preparations for immunotherapy and the treatment of cancer, immunological diseases and disorders, genetic disorders, rare diseases, and infectious diseases for humans and animals

Filing History

TEAS STATEMENT OF USE RECEIVED
Nov 7, 2025 EISU
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 7, 2025 EXRA
SOU EXTENSION 2 GRANTED
May 6, 2025 EX2G
SOU EXTENSION 2 FILED
May 6, 2025 EXT2
SOU TEAS EXTENSION RECEIVED
May 6, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 6, 2024 EXRA
SOU EXTENSION 1 GRANTED
Nov 6, 2024 EX1G
SOU EXTENSION 1 FILED
Nov 6, 2024 EXT1
SOU TEAS EXTENSION RECEIVED
Nov 6, 2024 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
May 7, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 12, 2024 NPUB
PUBLISHED FOR OPPOSITION
Mar 12, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 21, 2024 NONP
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 21, 2024 NPUB
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 5, 2024 CNSA
EXAMINER'S AMENDMENT ENTERED
Feb 5, 2024 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Feb 5, 2024 GNEN
EXAMINERS AMENDMENT E-MAILED
Feb 5, 2024 GNEA
EXAMINERS AMENDMENT -WRITTEN
Feb 5, 2024 CNEA
PREVIOUS ALLOWANCE COUNT WITHDRAWN
Feb 5, 2024 ZZZX
WITHDRAWN FROM PUB - OG REVIEW QUERY
Jan 16, 2024 PBCR
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 3, 2024 CNSA
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Dec 6, 2023 EWAF
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Dec 6, 2023 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Dec 6, 2023 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Dec 6, 2023 REAP
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 5, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 4, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 4, 2023 TROA
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Sep 1, 2023 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Sep 1, 2023 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 2, 2023 GNRN
NON-FINAL ACTION E-MAILED
Jun 2, 2023 GNRT
NON-FINAL ACTION WRITTEN
Jun 2, 2023 CNRT
ASSIGNED TO EXAMINER
May 31, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 31, 2022 NWOS
NEW APPLICATION ENTERED
Aug 15, 2022 NWAP